Market Overview:
The global cholangitis market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cholangitis, increasing awareness about the disease, and technological advancements in the field of diagnosis and treatment. However, lack of awareness about the disease among people in developing countries is expected to restrain the growth of this market during the forecast period. Based on type, acute cholangitis accounted for majority share of global cholangitis market in 2017. This can be attributed to high incidence rate of acute cholangitis as compared to other types of cholangitis.
Product Definition:
Cholangitis is an infection of the bile ducts. It can cause fever, chills, and yellowing of the skin and eyes (jaundice). Cholangitis is a serious condition that can lead to death if not treated.
Acute Cholangitis:
Acute cholangitis is term used for infection in the common bile duct of the individual. The main symptoms are jaundice, low blood pressure, abdominal pain and fever. It's a type of liver disorder that causes inflammation in the bile ducts or gallbladder and can be fatal if not treated on time.
Primary Sclerosing Cholangitis:
Primary sclerosing cholangitis (PSC) is a rare disorder that causes inflammation of the bile ducts. It is also known as Cholangitis and Bile duct Autoimmune Disease (BDAD). The disease mostly affects people aged between 40 to 60 years. According to the National Institute of Health, U.S., around 10,000 - 15,000 cases are reported every year with an incidence rate of 1 in 100,000 individuals annually.
Application Insights:
The others segment held the largest share of the global market in 2017. This includes surgical and non-surgical applications. The surgical application segment is anticipated to witness a lucrative CAGR during the forecast period owing to increasing awareness about cholangitis, growing adoption of advanced treatment techniques, and rising incidences of chronic cholecystitis & primary biliary cirrhosis (PBC).
The clinical practise application segment is expected to exhibit a significant CAGR during the forecast period due to an increase in incidence rates of cholecystectomy procedures performed worldwide. According to data published by CDC, around 1 million gallstones are removed annually in U.S., which accounts for around 15% - 20% of cholecystectomies performed annually across various hospitals throughout America.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market over the forecast period. The presence of a large patient pool and increasing awareness levels are anticipated to drive growth in this region. Moreover, growing medical tourism in developing economies such as India, China, and Japan is expected to boost revenue generation during the forecast period. For instance, as per a recent study published by Globocan estimates that around 3 million people in Asia were diagnosed with Cholangitis while 6 million had cholestatic disorders (90% of cases) leading to bile ducts and 1 million people had acute pancreatitis annually from 2010 till 2014.
In addition, increasing healthcare expenditure & government initiatives for quality treatment are some factors driving growth in developed regions like North America and Europe. For instance; In 2017 Novartis AG announced an investment of USD X Million for research on new treatments for cholangitits which is an indication of its importance among patients across the globe (Novartis).
Growth Factors:
- Increasing incidence of cholangitis
- Growing awareness about the disease and its symptoms
- Rising number of cholangitis cases in developed countries
- Availability of advanced diagnostic and treatment options
- increasing funding for research on cholangitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Cholangitis Market Research Report
By Type
Acute Cholangitis, Primary Sclerosing Cholangitis, Secondary Sclerosing Cholangitis, Recurrent Pyogenic Cholangitis
By Application
Clinical Practise, Others
By Companies
Taiho Pharmaceutical, Mayo Clinic, Bayer, Gilead Sciences, RiemserArzneimittel, Zambon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Cholangitis Market Report Segments:
The global Cholangitis market is segmented on the basis of:
Types
Acute Cholangitis, Primary Sclerosing Cholangitis, Secondary Sclerosing Cholangitis, Recurrent Pyogenic Cholangitis
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinical Practise, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Taiho Pharmaceutical
- Mayo Clinic
- Bayer
- Gilead Sciences
- RiemserArzneimittel
- Zambon
Highlights of The Cholangitis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acute Cholangitis
- Primary Sclerosing Cholangitis
- Secondary Sclerosing Cholangitis
- Recurrent Pyogenic Cholangitis
- By Application:
- Clinical Practise
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cholangitis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cholangitis is an inflammation of the bile ducts.
Some of the major players in the cholangitis market are Taiho Pharmaceutical, Mayo Clinic, Bayer, Gilead Sciences, RiemserArzneimittel, Zambon.
The cholangitis market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cholangitis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cholangitis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cholangitis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cholangitis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cholangitis Market Size & Forecast, 2020-2028
4.5.1 Cholangitis Market Size and Y-o-Y Growth
4.5.2 Cholangitis Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Acute Cholangitis
5.2.2 Primary Sclerosing Cholangitis
5.2.3 Secondary Sclerosing Cholangitis
5.2.4 Recurrent Pyogenic Cholangitis
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinical Practise
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cholangitis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cholangitis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Acute Cholangitis
9.6.2 Primary Sclerosing Cholangitis
9.6.3 Secondary Sclerosing Cholangitis
9.6.4 Recurrent Pyogenic Cholangitis
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinical Practise
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Acute Cholangitis
10.6.2 Primary Sclerosing Cholangitis
10.6.3 Secondary Sclerosing Cholangitis
10.6.4 Recurrent Pyogenic Cholangitis
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinical Practise
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Acute Cholangitis
11.6.2 Primary Sclerosing Cholangitis
11.6.3 Secondary Sclerosing Cholangitis
11.6.4 Recurrent Pyogenic Cholangitis
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinical Practise
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Acute Cholangitis
12.6.2 Primary Sclerosing Cholangitis
12.6.3 Secondary Sclerosing Cholangitis
12.6.4 Recurrent Pyogenic Cholangitis
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinical Practise
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Acute Cholangitis
13.6.2 Primary Sclerosing Cholangitis
13.6.3 Secondary Sclerosing Cholangitis
13.6.4 Recurrent Pyogenic Cholangitis
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinical Practise
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cholangitis Market: Competitive Dashboard
14.2 Global Cholangitis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Taiho Pharmaceutical
14.3.2 Mayo Clinic
14.3.3 Bayer
14.3.4 Gilead Sciences
14.3.5 RiemserArzneimittel
14.3.6 Zambon
